drugset / Trial / NCT00952380
Fragmin for the Treatment of Acute VTE in Pediatric Cancer Patients
NaSingle-groupOpen-labelTreatment
Summary
Three month treatment of acute VTE with Fragmin in pediatric cancer patients
Timeline
- Start
- 2009-08
- Primary completion
- 2018-03
- Completion
- 2018-03
Publications
- Hartman LR, Nurmeev I, Svirin P, Wolter KD, Yan JL, Jani D, Goldenberg NA, Sherman N. A phase 2 pharmacodynamic dose-finding, safety, and efficacy study of dalteparin for pediatric venous thromboembolism treatment in children with and without cancer. Pediatr Blood Cancer. 2022 Aug;69(8):e29764. doi: 10.1002/pbc.29764. Epub 2022 Jun 9.
- Damle B, Jen F, Sherman N, Jani D, Sweeney K. Population Pharmacokinetic Analysis of Dalteparin in Pediatric Patients With Venous Thromboembolism. J Clin Pharmacol. 2021 Feb;61(2):172-180. doi: 10.1002/jcph.1716. Epub 2020 Aug 21.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dalteparin sodium | Other / unclassified | 100 iu/kg | Subcutaneous |
| Subject | Dalteparin sodium | Other / unclassified | 125 iu/kg | Subcutaneous |
| Subject | Dalteparin sodium | Other / unclassified | 150 iu/kg | Subcutaneous |